QLT Aczone Clears FDA With Restricted Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling calls for testing for glucose 6-phosphate dehydrogenase deficiency before initiating treatment with Aczone (dapsone); patients with the enzyme deficiency should be monitored with regular blood counts. Patients are also advised to consider other acne therapies.
You may also be interested in...
QLT Asks FDA To Remove Blood Screening Requirement For Acne Treatment Aczone
Firm hopes results of Phase IV study convince FDA to approve a more marketable label for the topical acne treatment.
QLT Asks FDA To Remove Blood Screening Requirement For Acne Treatment Aczone
Firm hopes results of Phase IV study convince FDA to approve a more marketable label for the topical acne treatment.
Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.